Brooke Huuskes

Brooke Huuskes


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
BHBrooke Huuskes
Brooke Huuskes
NSNicole Scholes‐Robertson
Nicole Scholes‐Robertson
CGChandana Guha
Chandana Guha
ABAmanda Baumgart
Amanda Baumgart
GWGermaine Wong
Germaine Wong
ATAllison Tong
Allison Tong
The COVID-19 pandemic has challenged the delivery of health services. Telehealth allows delivery of care without in-person contacts and minimizes the risk of vial transmission. We aimed to describe the perspectives of kidney transplant recipients on the benefits, challenges, and risks of telehealth. We conducted five online focus groups with 34 kidney transplant recipients who had experienced a telehealth appointment. Transcripts were thematically analyzed. We identified five themes: minimizing burden (convenient and easy, efficiency of appointments, reducing exposure to risk, limiting work disruptions, and alleviating financial burden); attuning to individual context (depending on stability of health, respect patient choice of care, and ensuring a conducive environment); protecting personal connection and trust (requires established rapport with clinicians, hampering honest conversations, diminished attentiveness without incidental interactions, reassurance of follow-up, and missed opportunity to share lived experience); empowerment and readiness (increased responsibility for self-management, confidence in physical assessment, mental preparedness, and forced independence); navigating technical challenges (interrupted communication, new and daunting technologies, and cognizant of patient digital literacy). Telehealth is convenient and minimizes time, financial, and overall treatment burden. Telehealth should ideally be available after the pandemic, be provided by a trusted nephrologist and supported with resources to help patients prepare for appointments.

10 April 2019 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
BHBrooke Huuskes
Brooke Huuskes
RDRyan J. DeBuque
Ryan J. DeBuque
PKPeter G. Kerr
Peter G. Kerr
CSChrishan S. Samuel
Chrishan S. Samuel
SRSharon D. Ricardo
Sharon D. Ricardo
Testing angiogenic potential and function of cells in culture is important for the understanding of the mechanisms that can modulate angiogenesis, especially when discovering novel anti- or pro-angiogenic therapeutics. Commonly used angiogenic assays include tube formation, proliferation, migration, and wound healing, and although well-characterized, it is important that methodology is standardized and reproducible. Human endothelial progenitor cells (EPCs) are critical for post-natal vascular homeostasis and can be isolated from human peripheral blood. Endothelial colony forming cells (ECFCs) are a subset of EPCs and are of interest as a possible therapeutic target for hypoxic diseases such as kidney disease, as they have a high angiogenic potential. However, once ECFCs are identified in culture, the exact timing of passaging has not been well-described and the optimal conditions to perform angiogenic assays such as seeding density, growth media (GM) concentrations and end-points of these assays is widely varied in the literature. Here, we describe the process of isolating, culturing and passaging ECFCs from patients with end-stage renal disease (ESRD), aided by image analysis. We further describe optimal conditions, for human bladder endothelial cells (hBECs), challenged in angiogenic assays and confirm that cell density is a limiting factor in accurately detecting angiogenic parameters. Furthermore, we show that GM along is enough to alter the angiogenic potential of cells, seeded at the same density. Lastly, we report on the success of human ECFCs in angiogenic assays and describe the benefits of live-cell imaging combined with time-lapse microscopy for this type of investigation.

12 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAmrilmaen Badawi
Amrilmaen Badawi
OJOsfred Chariany Jefferson
Osfred Chariany Jefferson
BHBrooke Huuskes
Brooke Huuskes
SRSharon D. Ricardo
Sharon D. Ricardo
PKPeter G. Kerr
Peter G. Kerr
Padma MurthiPadma Murthi
Padma Murthi
Circulating bone marrow-derived endothelial progenitor cells (EPCs) facilitate vascular repair in several organs including the kidney but are progressively diminished in end-stage kidney disease (ESKD) patients, which correlates with cardiovascular outcomes and related mortality. We thus determined if enhancing the tissue-reparative effects of human bone marrow-derived mesenchymal stromal cells (BM-MSCs) with the vasculogenic effects of recombinant human relaxin (RLX) could promote EPC proliferation and function. CD34+ EPCs were isolated from the blood of healthy and ESKD patients, cultured until late EPCs had formed, then stimulated with BM-MSC-derived condition media (CM; 25%), RLX (1 or 10 ng/mL), or both treatments combined. Whilst RLX alone stimulated EPC proliferation, capillary tube formation and wound healing in vitro, these measures were more rapidly and markedly enhanced by the combined effects of BM-MSC-derived CM and RLX in EPCs derived from both healthy and ESKD patients. These findings have important clinical implications, having identified a novel combination therapy that can restore and enhance EPC number and function in ESKD patients.

26 June 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AHAnastasia Hughes
Anastasia Hughes
AGAndrea Matus Gonzalez
Andrea Matus Gonzalez
NANoa Amir
Noa Amir
MGMacarena Arancibia Garcia
Macarena Arancibia Garcia
FCFergus J. Caskey
Fergus J. Caskey
OIon behalf of the SONG-CKD Life Participation workshop investigators*
on behalf of the SONG-CKD Life Participation workshop investigators*
Introduction: Life participation is of critical importance to patients with chronic kidney disease (CKD) not requiring kidney replacement therapy (KRT), their caregivers and health professionals. However, life participation is rarely and inconsistently assessed in trials in CKD. The aim was to establish a core outcome measure for life participation in patients with CKD not requiring KRT. Methods: An online (English language) and an in-person (Spanish language) consensus workshop, one-hour in length, were held in March and April 2024 respectively, were held to discuss and establish a meaningful, relevant and feasible core patient-reported outcome measure for life participation for trials in CKD. Transcripts were analyzed thematically. Results: Workshops included 130 participants, including 74 patients and caregivers, and 56 health professionals, from 18 countries. Four themes were identified. Enabling interpretation within individual contexts and circumstances included considering relevance to patients’ own priorities, capturing key life activities common to all patients, reflecting the goal of leading a fulfilling life, acknowledging the variability and multiplicity of domains, and facilitating linguistic and cultural translation. Having broad clinical relevance across CKD meant covering the spectrum of CKD stages and diagnoses, and allowing comparison across treatment stages. Supporting widespread implementation entailed minimizing burden of administration and completion, establishing psychometric robustness, seeking endorsement to legitimize the measure, and ensuring accessibility and acceptability across different settings. Highlighting opportunities to address life participation captured promoting person-centered clinical care and generating ideas for novel interventions to improve life participation. Conclusion: A core outcome measure for life participation in patients with CKD should enable a patient to interpret life participation in their own context, have applicability across the CKD population, and be psychometrically robust and feasible to implement. Measuring life participation in a consistent and meaningful way across trials can better support patient-centered decision making and outcomes.

5 August 2026 in Kidney360
Verified
Journal Article
Open access
DCDale Coghlan
Dale Coghlan
AJAllison Jauré
Allison Jauré
SJShilpanjali Jesudason
Shilpanjali Jesudason
JCJonathan C. Craig
Jonathan C. Craig
AHAnastasia Hughes
Anastasia Hughes
NSNicole Scholes-Robertson
Nicole Scholes-Robertson
Key Points: CKD research translation into practice and policy is slow and fragmented, with limited codesign and few examples of equity-focused implementation. Three stakeholder-driven strategies to improve implementation of research findings were identified. Embedding these strategies may accelerate CKD translation through stronger consumer governance and equity-focused implementation. Background: Routine implementation of CKD research into practice and policy is delayed, fragmented, and inconsistent. The aim of this workshop was to identify strategies to strengthen the implementation of research findings into practice and policy from the perspectives of patients and their caregivers and health professionals. Methods: A workshop was conducted with patients ( n =18), caregivers ( n =9), and health professionals ( n =102) from Australia and New Zealand. Thirteen simultaneous breakout groups of six to ten participants were held online and in person to discuss strategies for implementing research findings into practice and policy in CKD. Transcripts were thematically analyzed. Results: Three inter-related strategies were identified. Coproduction for credibility emphasizes genuine involvement of patients and caregivers in governance and a priority setting to enhance the legitimacy of research, foster trust, and build lasting partnerships to extend beyond a single project. Diversity and equity for broader transferability encompasses culturally tailored, community-grounded involvement with underrepresented groups, resourced with dedicated time and funds for outreach and translation to ensure cultural relevance and generalizability. Accessible and actionable integration of evidence focuses on clearly articulating research outputs into clinical and policy implications by packaging findings in practical and accessible formats ( e.g ., plain language summaries and visual materials), to translate evidence into action. Conclusions: Embedding these strategies may strengthen the routine translation of research evidence into practice and policy, ultimately improving care and outcomes for patients with kidney disease.

13 February 2026 in American Journal of Transplantation
Verified
Journal Article
Closed access
EHErandi Hewawasam
Erandi Hewawasam
CDChristopher Davies
Christopher Davies
RBRithiha Balu
Rithiha Balu
ATAdela Tolic
Adela Tolic
ASAmanda Sluiter
Amanda Sluiter
SJShilpanjali Jesudason
Shilpanjali Jesudason